NasdaqGM · Biotechnology

Connect Biopharma (CNTB)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+207.2%

$7.25 average target

$2.36+0.08 (+3.5%)Latest market snapshot · Yahoo Finance

Market cap$148.6M

Cash$31.5M

Quarterly burn$16.0M

Pipeline assets10

Short float4.6%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 207.2% upsideTargets are estimates—not guarantees—and can change after company updates.

$7.25Average target

Wall Street consensus

Strong BuyBased on 8 analyst opinions

8ratings

Buy 8Hold 0Sell 0

Price-target range

$7.25

+207.2%

Low $4.00High $10.00

CurrentAverage

Bear case$4.00+69.5%

Base case$7.25+207.2%

Bull case$10.00+323.7%

Analyst coverage8published opinions

Bullish share100%buy recommendations

Target spread$6low-to-high dispersion

Consensus score1.11.0 is strongest

Recommendation mix

Current rating breakdown

8 tracked ratings

Company profile

About Connect Biopharma

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.